Cisplatino shortage — IT supply status & alternatives

Cisplatino

ATC L01XA01

In supply · Australia

Cisplatino Accord Healthcare Italia

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇪🇸 ES

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

Carboplatino

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

ATC level 5
Active ingredient (INN)	Cisplatino
Brand names	Cisplatino Accord Healthcare Italia

ATC level 4	L01XA

Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇦🇺

Cisplatin 50mg in 0.9% Sodium Chloride in Polyolefin Bag (Freeflex) for Intravenous InfusionBatch Nu

Slade Health Pty Ltd · Apr 2026

Class IIdetails ↗

🇦🇺

CISPLATIN 70MG IN 0.9% SODIUM CHLORIDE IN POLYOLEFIN BAG (FREEFLEX) FOR INTRAVENOUS INFUSIONBatch Nu

Slade Health Pty Ltd · Jan 2026

Class IIdetails ↗

🇺🇸

Cisplatin Active Pharmaceutical Ingredient Packaged In Varyi

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

Verified timeline regulator events

🇮🇹 13 May 2026

medium reported

🇮🇹 4 Mar 2026

critical reported

🇮🇹 28 Feb 2026

medium reported

🇮🇹 15 Oct 2025

critical reported

🇮🇹 7 Apr 2025

medium reported

🇪🇸 10 Nov 2024

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.